184 related articles for article (PubMed ID: 37377605)
1. Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1
Wang J; Cheng X; Jin Y; Xia B; Qin R; Zhang W; Hu H; Mao X; Zhou L; Yan J; Zhang X; Xu J
Cancer Res Commun; 2023 Jun; 3(6):991-1003. PubMed ID: 37377605
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial.
Cheng X; Wang J; Qiu C; Jin Y; Xia B; Qin R; Hu H; Yan J; Zhang X; Xu J
Clin Immunol; 2022 May; 238():108992. PubMed ID: 35367396
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J
Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901
[TBL] [Abstract][Full Text] [Related]
4. SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report.
Li D; Liu M; Wang J; Guo J; Xu N; Lu J
Front Immunol; 2022; 13():1073094. PubMed ID: 36578494
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
Yu W; Ye F; Yuan X; Ma Y; Mao C; Li X; Li J; Dai C; Qian F; Li J; Fan X; Zhou Y; Wang D; Guo Z; An H; Zhang M; Chen D; Xia S
BMC Cancer; 2021 Jul; 21(1):877. PubMed ID: 34332557
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
7. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Exley MA; Friedlander P; Alatrakchi N; Vriend L; Yue S; Sasada T; Zeng W; Mizukami Y; Clark J; Nemer D; LeClair K; Canning C; Daley H; Dranoff G; Giobbie-Hurder A; Hodi FS; Ritz J; Balk SP
Clin Cancer Res; 2017 Jul; 23(14):3510-3519. PubMed ID: 28193627
[No Abstract] [Full Text] [Related]
8. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD; Petroni GR; Mauldin IS; Chianese-Bullock KA; Olson WC; Smith KT; Dengel LT; Haden K; Grosh WW; Kaur V; Varhegyi N; Gaughan EM; Slingluff CL
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100309
[TBL] [Abstract][Full Text] [Related]
9. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
10. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors.
Song Q; Yang B; Sheng W; Zhou Z; Zhang T; Qin B; Ji L; Li P; Wang D; Zhang X; Sun S; Zhang G; Zhao X; Gan Q; Xiong Q; Guan Y; Xia X; Yi X; Chen X; Guo W; Jiao S
Immunotherapy; 2022 May; 14(7):553-565. PubMed ID: 35321561
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
16. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Sinha M; Betts C; Zhang L; Griffith MJ; Solman I; Chen B; Liu E; Tamaki W; Stultz J; Marquez J; Sivagnanam S; Cheung A; Pener D; Fahlman A; Taber E; Lerner K; Crocker M; Todd K; Rajagopalan B; Ware C; Bridge M; Vo J; Dragomanovich H; Sudduth-Klinger J; Vaccaro G; Lopez CD; Tempero M; Coussens LM; Fong L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593070
[TBL] [Abstract][Full Text] [Related]
17. Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio.
De Biasi S; Bianchini E; Nasi M; Digaetano M; Gibellini L; Carnevale G; Borghi V; Guaraldi G; Pinti M; Mussini C; Cossarizza A
AIDS; 2016 Nov; 30(17):2599-2610. PubMed ID: 27782963
[TBL] [Abstract][Full Text] [Related]
18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.
Song D; Yang X; Guo X; Sun H
Immunotherapy; 2022 Nov; 14(16):1307-1313. PubMed ID: 36341552
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
